November 11, 2022 01:45 PM EST
R&D

IRA im­pact: As­traZeneca and Mer­ck CEOs warn of on­col­o­gy drug de­vel­op­ment shifts

Zachary Brennan

Senior Editor

This lat­est quar­ter­ly earn­ings sea­son for phar­ma has been a time for com­pa­nies to vent about Pres­i­dent Biden’s new drug price ne­go­ti­a­tion law, with some …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times